Ann Otol Rhinol Laryngol:腺样体切除术后与顽固性鼻塞相关的因素分析

2020-08-05 AlexYang MedSci原创

最近,有研究人员阐释了接受腺样体切除术的儿科患者难治性鼻炎的相关因素,并与症状缓解者进行了比较。

最近,有研究人员阐释了接受腺样体切除术的儿科患者难治性鼻炎的相关因素,并与症状缓解者进行了比较。

研究人员对接受腺样体切除术的小于18岁的儿科患者进行了病例系列研究,时间为2012年10月至2018年12月,地点为波士顿医学中心。研究群体中排除了接受扁桃体切除术和腺样体切除术的患者,以及因鼻炎以外的其他适应症接受腺样体切除术的患者。研究人员将103名腺样体切除术后出现难治性症状的患者与139名症状得到缓解的患者进行了比较。研究发现,难治性症状的患者使用比例明显更高(89.3%,P=0.0011),术前(1.50,P=0.026)和术后(1.10,P<0.0001)药物的平均次数也显著更多,其中包括了鼻腔生理盐水、鼻内类固醇、抗组胺药和/或抗生素。这些难治性患者更有可能接受术后过敏评估(50%,P=0.0068)和二次手术(30.1%,P<0.0001),并且有更高比例的过敏史报告(24.3%,P=0.0089)。

最后,研究人员指出,腺样体切除术后难治性慢性鼻炎患者术前药物的使用和数量、报告的过敏史和术后过敏评估的比例显著更高。他们的研究鉴定了发展为难治性症状的患者的相关差异,这可能有助于手术治疗的临床决策。

原始出处:

Aneesh Patel , Christopher D Brook , Jessica R Levi et al. Factors Associated with Refractory Nasal Congestion Following Adenoidectomy. Ann Otol Rhinol Laryngol. Jul 2020

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1723559, encodeId=94a81e235594e, content=<a href='/topic/show?id=80a485e0564' target=_blank style='color:#2F92EE;'>#腺样体切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85705, encryptionId=80a485e0564, topicName=腺样体切除术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b4d33471162, createdName=tastas, createdTime=Sat Jun 12 08:05:54 CST 2021, time=2021-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877316, encodeId=ee7a18e7316bc, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Tue Sep 15 10:05:54 CST 2020, time=2020-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632907, encodeId=e53e163290e00, content=<a href='/topic/show?id=5e1110013180' target=_blank style='color:#2F92EE;'>#顽固性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100131, encryptionId=5e1110013180, topicName=顽固性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e4121955726, createdName=limedical1981, createdTime=Thu Feb 11 03:05:54 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361145, encodeId=e31c1361145b8, content=<a href='/topic/show?id=3e891034351c' target=_blank style='color:#2F92EE;'>#鼻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103435, encryptionId=3e891034351c, topicName=鼻塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Fri Aug 07 05:05:54 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806502, encodeId=8586806502db, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Thu Aug 06 12:33:02 CST 2020, time=2020-08-06, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1723559, encodeId=94a81e235594e, content=<a href='/topic/show?id=80a485e0564' target=_blank style='color:#2F92EE;'>#腺样体切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85705, encryptionId=80a485e0564, topicName=腺样体切除术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b4d33471162, createdName=tastas, createdTime=Sat Jun 12 08:05:54 CST 2021, time=2021-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877316, encodeId=ee7a18e7316bc, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Tue Sep 15 10:05:54 CST 2020, time=2020-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632907, encodeId=e53e163290e00, content=<a href='/topic/show?id=5e1110013180' target=_blank style='color:#2F92EE;'>#顽固性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100131, encryptionId=5e1110013180, topicName=顽固性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e4121955726, createdName=limedical1981, createdTime=Thu Feb 11 03:05:54 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361145, encodeId=e31c1361145b8, content=<a href='/topic/show?id=3e891034351c' target=_blank style='color:#2F92EE;'>#鼻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103435, encryptionId=3e891034351c, topicName=鼻塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Fri Aug 07 05:05:54 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806502, encodeId=8586806502db, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Thu Aug 06 12:33:02 CST 2020, time=2020-08-06, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1723559, encodeId=94a81e235594e, content=<a href='/topic/show?id=80a485e0564' target=_blank style='color:#2F92EE;'>#腺样体切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85705, encryptionId=80a485e0564, topicName=腺样体切除术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b4d33471162, createdName=tastas, createdTime=Sat Jun 12 08:05:54 CST 2021, time=2021-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877316, encodeId=ee7a18e7316bc, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Tue Sep 15 10:05:54 CST 2020, time=2020-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632907, encodeId=e53e163290e00, content=<a href='/topic/show?id=5e1110013180' target=_blank style='color:#2F92EE;'>#顽固性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100131, encryptionId=5e1110013180, topicName=顽固性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e4121955726, createdName=limedical1981, createdTime=Thu Feb 11 03:05:54 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361145, encodeId=e31c1361145b8, content=<a href='/topic/show?id=3e891034351c' target=_blank style='color:#2F92EE;'>#鼻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103435, encryptionId=3e891034351c, topicName=鼻塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Fri Aug 07 05:05:54 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806502, encodeId=8586806502db, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Thu Aug 06 12:33:02 CST 2020, time=2020-08-06, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1723559, encodeId=94a81e235594e, content=<a href='/topic/show?id=80a485e0564' target=_blank style='color:#2F92EE;'>#腺样体切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85705, encryptionId=80a485e0564, topicName=腺样体切除术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b4d33471162, createdName=tastas, createdTime=Sat Jun 12 08:05:54 CST 2021, time=2021-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877316, encodeId=ee7a18e7316bc, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Tue Sep 15 10:05:54 CST 2020, time=2020-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632907, encodeId=e53e163290e00, content=<a href='/topic/show?id=5e1110013180' target=_blank style='color:#2F92EE;'>#顽固性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100131, encryptionId=5e1110013180, topicName=顽固性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e4121955726, createdName=limedical1981, createdTime=Thu Feb 11 03:05:54 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361145, encodeId=e31c1361145b8, content=<a href='/topic/show?id=3e891034351c' target=_blank style='color:#2F92EE;'>#鼻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103435, encryptionId=3e891034351c, topicName=鼻塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Fri Aug 07 05:05:54 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806502, encodeId=8586806502db, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Thu Aug 06 12:33:02 CST 2020, time=2020-08-06, status=1, ipAttribution=)]
    2020-08-07 liuhuangbo
  5. [GetPortalCommentsPageByObjectIdResponse(id=1723559, encodeId=94a81e235594e, content=<a href='/topic/show?id=80a485e0564' target=_blank style='color:#2F92EE;'>#腺样体切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85705, encryptionId=80a485e0564, topicName=腺样体切除术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b4d33471162, createdName=tastas, createdTime=Sat Jun 12 08:05:54 CST 2021, time=2021-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877316, encodeId=ee7a18e7316bc, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Tue Sep 15 10:05:54 CST 2020, time=2020-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632907, encodeId=e53e163290e00, content=<a href='/topic/show?id=5e1110013180' target=_blank style='color:#2F92EE;'>#顽固性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100131, encryptionId=5e1110013180, topicName=顽固性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e4121955726, createdName=limedical1981, createdTime=Thu Feb 11 03:05:54 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361145, encodeId=e31c1361145b8, content=<a href='/topic/show?id=3e891034351c' target=_blank style='color:#2F92EE;'>#鼻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103435, encryptionId=3e891034351c, topicName=鼻塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Fri Aug 07 05:05:54 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806502, encodeId=8586806502db, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Thu Aug 06 12:33:02 CST 2020, time=2020-08-06, status=1, ipAttribution=)]
    2020-08-06 ms3000000449926787

    学习

    0

相关资讯

JAHA:电子烟使用率和相关因素分析

由此可见,在2013年至2014年期间,电子烟使用在美国年轻人、社会经济地位较低以及现在和既往吸烟者中更为常见。这些发现将有助于为未来的研究以及为公共政策和监管行动提供信息。

Crit Care:念珠菌病患者发展为感染性休克的相关因素

年龄和腹部感染源是与感染性休克发生密切相关的重要因素。该研究的结果表明感染性休克的发生与宿主因素和感染源可能比念珠菌固有毒性因素更为重要。

Stroke:机械血栓切除术后二十四小时再闭塞的相关因素与长期预后

由此可见,成功MT后24小时内再闭塞与他汀类药物预处理、闭塞部位、更复杂的手术操作、动脉粥样硬化病因以及再通后残留的血栓或狭窄独立相关。再闭塞对长期结局的影响凸显了监测和预防这种早期并发症的必要性。

J Rheumatol:与巨细胞动脉炎复发和糖皮质激素依赖相关的因素

LVV是复发和GC依赖的独立预测因子。需要进一步的前瞻性研究来证实这些发现,并确定LVV患者是否需要不同的治疗方法。

J Periodontol:转诊牙周专科医师的相关非临床因素

目前为止,少有研究报道在口腔全科医生和牙周专科医生之间转诊的关系。也从未考虑临床和非临床因素与转诊过程的关系。然而,对其更好的理解会改善口腔全科医生和牙周专科医生之间的关系,并且有助于对患者的管理。这篇研究的目的是为了调查非临床因素与口腔全科医生向牙周专科医生转诊的关系。

Crit Care:与中央导管相关血流感染复发和死亡的相关因素分析

由此可见,HA-CLABSI患者的抗菌治疗持续时间越长,感染后最初60天内无复发生存率越高。治疗15天后,这种效果似乎达到平台期。需要前瞻性研究来明确CLABSI患者的最佳抗菌治疗持续时间。